Sanofi Makes New $1.23 Million Investment in Inozyme Pharma, Inc. (NASDAQ:INZY)

Sanofi acquired a new stake in Inozyme Pharma, Inc. (NASDAQ:INZY - Free Report) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 443,255 shares of the company's stock, valued at approximately $1,228,000. Inozyme Pharma comprises approximately 0.7% of Sanofi's investment portfolio, making the stock its 8th largest position. Sanofi owned 0.69% of Inozyme Pharma at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Affinity Asset Advisors LLC grew its position in shares of Inozyme Pharma by 40.7% during the 4th quarter. Affinity Asset Advisors LLC now owns 3,972,318 shares of the company's stock worth $11,003,000 after purchasing an additional 1,150,000 shares in the last quarter. Rock Springs Capital Management LP increased its stake in Inozyme Pharma by 1.6% during the 4th quarter. Rock Springs Capital Management LP now owns 3,861,983 shares of the company's stock worth $10,698,000 after acquiring an additional 59,100 shares during the period. Millennium Management LLC raised its holdings in Inozyme Pharma by 7.9% in the 4th quarter. Millennium Management LLC now owns 1,882,274 shares of the company's stock valued at $5,214,000 after acquiring an additional 137,821 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Inozyme Pharma by 0.7% during the 4th quarter. Geode Capital Management LLC now owns 1,179,622 shares of the company's stock valued at $3,268,000 after acquiring an additional 8,450 shares during the period. Finally, Knott David M Jr lifted its position in shares of Inozyme Pharma by 23.1% during the 4th quarter. Knott David M Jr now owns 695,000 shares of the company's stock valued at $1,925,000 after acquiring an additional 130,451 shares during the period. 88.30% of the stock is currently owned by institutional investors and hedge funds.

Inozyme Pharma Price Performance

Shares of NASDAQ:INZY traded up $0.01 during trading on Thursday, hitting $3.96. 1,611,859 shares of the company were exchanged, compared to its average volume of 809,486. Inozyme Pharma, Inc. has a 1-year low of $0.72 and a 1-year high of $6.24. The company has a market capitalization of $255.34 million, a P/E ratio of -2.54 and a beta of 1.35. The company has a quick ratio of 7.68, a current ratio of 7.68 and a debt-to-equity ratio of 0.51. The business's 50 day moving average is $1.27 and its 200-day moving average is $1.88.

Inozyme Pharma (NASDAQ:INZY - Get Free Report) last issued its earnings results on Wednesday, May 14th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.43) by ($0.01). Equities analysts forecast that Inozyme Pharma, Inc. will post -1.59 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts recently commented on INZY shares. Jefferies Financial Group restated a "hold" rating and issued a $4.00 price target (down previously from $15.00) on shares of Inozyme Pharma in a research report on Friday, May 16th. Piper Sandler dropped their target price on shares of Inozyme Pharma from $30.00 to $23.00 and set an "overweight" rating for the company in a research report on Tuesday, March 11th. HC Wainwright reaffirmed a "buy" rating and set a $16.00 price target on shares of Inozyme Pharma in a report on Thursday, April 10th. Needham & Company LLC downgraded shares of Inozyme Pharma from a "moderate buy" rating to a "hold" rating in a research report on Friday, May 16th. Finally, Raymond James reduced their target price on Inozyme Pharma from $24.00 to $12.00 and set an "outperform" rating on the stock in a report on Wednesday, March 12th. Five investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Hold" and an average price target of $11.75.

Inozyme Pharma Company Profile

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.